Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1326-1330

  Kotowski, Ulana ^a   Heiduschka, Gregor ^a   Brunner, Markus ^a   Erovic, Boban M ^a   Martinek, Helga ^a   Thurnher, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Arsenic trioxide; Cisplatin; Head and neck cancer; Synergism

Indexed keywords

ARSENIC TRIOXIDE; CISPLATIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOHISTOCHEMISTRY; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

EID: 84859467012     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.643     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S:Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903, 2002.
3. Gensini GF, Conti AA and Lippi D: The contributions of Paul Ehrlich to infectious disease. J Infect 54: 221-224, 2007.
4. Docampo R and Moreno SN: Current chemotherapy of human African trypanosomiasis. Parasitol Res 90 (Supp 1): S10-S13, 2003.
5. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998.
6. Shen ZX, Chen GQ, Ni JH, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
7. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001.
8. Jiang XH, Wong BC, Yuen ST, et al: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 91: 173-179, 2001.
9. Seol JG, Park WH, Kim ES, et al: Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 265: 400-404, 1999.
10. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999.
11. Shen ZY, Shen J, Li QS, Chen CY, Chen JY and Yi Z: Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol 8: 31-35, 2002.
12. Uslu R, Sanli UA, Sezgin C, et al: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000.
13. Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM and Ellison R: Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125: 470-476, 2004.
14. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE and McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104: 1687-1692, 2005.
15. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77-84, 2007.
16. Schiller GJ, Slack J, Hainsworth JD, et al: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24: 2456-2464, 2006.
17. Whisler LC, Wood NB, Caldarelli DD, et al: Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope 108: 630-638, 1998.
18. Evens AM, Tallman MS and Gartenhaus RB: The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28: 891-900, 2004.
19. Soignet SL: Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 (Suppl 2): 11-16, 2001.
20. Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353, 1997.
21. Shao W, Fanelli M, Ferrara FF, et al: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90: 124-133, 1998.
22. Seol JG, Park WH, Kim ES, et al: Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 18: 249-255, 2001.
23. Wang W, Qin SK, Chen BA and Chen HY: Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol 7: 702-705, 2001.
24. Li H, Zhu X, Zhang Y, Xiang J and Chen H: Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction. J Exp Clin Cancer Res 28: 110, 2009.
25. Zhang N, Wu ZM, McGowan E, et al: Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci 100:2459-2464, 2009.
26. Chung WH, Sung BH, Kim SS, Rhim H and Kuh HJ: Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol 34: 1669-1679, 2009.